Literature DB >> 34972895

Tissue Characterization in Cardiology: Moving Beyond Function.

George Markousis-Mavrogenis1, Flora Bacopoulou2,3, Dimitrios Vlachakis4, Sophie Mavrogeni5,6.   

Abstract

Cardiovascular Magnetic Resonance (CMR) offers accurate and highly reproducible tissue characterization, beyond cardiac function. Late gadolinium enhancement (LGE), although represents a noninvasive biopsy for fibrosis quantification, it is unable to detect diffuse myocardial disease. Native T1 mapping and extracellular volume fraction (ECV) are able to provide important information about processes involving both myocardial cells and interstitium that otherwise cannot be identified. Changes in myocardial native T1 mapping reflect cardiac diseases such as acute coronary syndromes, myocardial infarction, myocarditis, diffuse fibrosis, systemic disease such as cardiac amyloidosis, all presented with high T1 and Anderson-Fabry disease and siderosis, presented with low T1 mapping. The ECV, an index generated by native and postcontrast T1 mapping, introduces a new way to measure the cellular and extracellular interstitial matrix (ECM). ECV has a prognostic value equal to Left ventricular ejection fraction (LVEF); however, LVEF underscores the interstitial matrix. This myocyte-ECM dichotomy has important implications for identifying therapeutic targets that are of great value for heart failure (HF) treatment. Furthermore, T2 mapping is superior compared with myocardial T1 and ECM for assessing the activity of myocarditis in recent-onset HF. These indices will affect significantly the clinical decision making. However, there is still lack of multicenter studies and community-wide approach including MRI vendors, clinicians, fundings, softwares, and contrast agent manufacturers.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Cardiovascular magnetic resonance; Extracellular volume fraction; Heart diseases; T1 mapping; T2 mapping

Mesh:

Substances:

Year:  2021        PMID: 34972895     DOI: 10.1007/978-3-030-78771-4_11

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  55 in total

1.  Evolution and revolution in CMR imaging.

Authors:  Eike Nagel; Jagat Narula
Journal:  JACC Cardiovasc Imaging       Date:  2013-07

2.  Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death.

Authors:  Leah Iles; Heinz Pfluger; Lisa Lefkovits; Michelle J Butler; Peter M Kistler; David M Kaye; Andrew J Taylor
Journal:  J Am Coll Cardiol       Date:  2011-02-15       Impact factor: 24.094

Review 3.  Assessment of myocardial fibrosis with cardiovascular magnetic resonance.

Authors:  Nathan Mewton; Chia Ying Liu; Pierre Croisille; David Bluemke; João A C Lima
Journal:  J Am Coll Cardiol       Date:  2011-02-22       Impact factor: 24.094

4.  Myocardial edema as detected by pre-contrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction.

Authors:  Martin Ugander; Paul S Bagi; Abiola J Oki; Billy Chen; Li-Yueh Hsu; Anthony H Aletras; Saurabh Shah; Andreas Greiser; Peter Kellman; Andrew E Arai
Journal:  JACC Cardiovasc Imaging       Date:  2012-06

5.  Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study.

Authors:  Deborah H Kwon; Carmel M Halley; Thomas P Carrigan; Victoria Zysek; Zoran B Popovic; Randolph Setser; Paul Schoenhagen; Randall C Starling; Scott D Flamm; Milind Y Desai
Journal:  JACC Cardiovasc Imaging       Date:  2009-01

6.  CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy.

Authors:  Tomas G Neilan; Otavio R Coelho-Filho; Stephan B Danik; Ravi V Shah; John A Dodson; Daniel J Verdini; Michifumi Tokuda; Caroline A Daly; Usha B Tedrow; William G Stevenson; Michael Jerosch-Herold; Brian B Ghoshhajra; Raymond Y Kwong
Journal:  JACC Cardiovasc Imaging       Date:  2013-08-08

7.  Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults.

Authors:  Erik B Schelbert; Jie J Cao; Sigurdur Sigurdsson; Thor Aspelund; Peter Kellman; Anthony H Aletras; Christopher K Dyke; Gudmundur Thorgeirsson; Gudny Eiriksdottir; Lenore J Launer; Vilmundur Gudnason; Tamara B Harris; Andrew E Arai
Journal:  JAMA       Date:  2012-09-05       Impact factor: 56.272

8.  Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance.

Authors:  Vanessa M Ferreira; Stefan K Piechnik; Erica Dall'Armellina; Theodoros D Karamitsos; Jane M Francis; Robin P Choudhury; Matthias G Friedrich; Matthew D Robson; Stefan Neubauer
Journal:  J Cardiovasc Magn Reson       Date:  2012-06-21       Impact factor: 5.364

Review 9.  Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement.

Authors:  James C Moon; Daniel R Messroghli; Peter Kellman; Stefan K Piechnik; Matthew D Robson; Martin Ugander; Peter D Gatehouse; Andrew E Arai; Matthias G Friedrich; Stefan Neubauer; Jeanette Schulz-Menger; Erik B Schelbert
Journal:  J Cardiovasc Magn Reson       Date:  2013-10-14       Impact factor: 5.364

10.  Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy.

Authors:  Ankur Gulati; Andrew Jabbour; Tevfik F Ismail; Kaushik Guha; Jahanzaib Khwaja; Sadaf Raza; Kishen Morarji; Tristan D H Brown; Nizar A Ismail; Marc R Dweck; Elisa Di Pietro; Michael Roughton; Ricardo Wage; Yousef Daryani; Rory O'Hanlon; Mary N Sheppard; Francisco Alpendurada; Alexander R Lyon; Stuart A Cook; Martin R Cowie; Ravi G Assomull; Dudley J Pennell; Sanjay K Prasad
Journal:  JAMA       Date:  2013-03-06       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.